Mutual Advisors LLC Makes New Investment in ImmunityBio, Inc. (NASDAQ:IBRX)

Mutual Advisors LLC acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,200 shares of the company’s stock, valued at approximately $41,000.

Other hedge funds have also bought and sold shares of the company. State Street Corp boosted its position in ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Barclays PLC boosted its position in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares in the last quarter. HighTower Advisors LLC purchased a new stake in ImmunityBio in the 3rd quarter worth approximately $136,000. Mirae Asset Global Investments Co. Ltd. boosted its position in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after purchasing an additional 4,545 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of ImmunityBio during the 3rd quarter worth approximately $143,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $3.16 on Thursday. The business has a fifty day moving average price of $3.39 and a 200 day moving average price of $4.02. ImmunityBio, Inc. has a one year low of $2.28 and a one year high of $10.53. The company has a market cap of $2.20 billion, a P/E ratio of -3.43 and a beta of 0.86.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IBRX shares. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research note on Monday. BTIG Research started coverage on ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 target price for the company. Finally, EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.